Skye Bioscience Launches Phase 2a Trial of Nimacimab for Obesity Treatment
I'm PortAI, I can summarize articles.
Skye Bioscience Inc. has launched a Phase 2a clinical trial for nimacimab, a CB1 inhibitor antibody aimed at treating obesity. The trial also assesses nimacimab in combination with the GLP-1R agonist Wegovy®. Preclinical results presented at the Keystone Obesity Therapeutics conference demonstrated nimacimab's efficacy alone and with tirzepatide in a mouse model of diet-induced obesity. Clinical trial results are pending. This information is for informational purposes only and should not be considered financial or legal advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments